secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0001493152-24-042600
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow draws $30M under Oaktree loan for Novartis Triescence milestone; amends credit terms
--------------------------------------------------------------------------------

- Drew $30M on Oct 25, 2024, under Oaktree Loan to partially fund $37M milestone to Novartis for Triescence commercial availability.
- Total drawn under Oaktree Loan now $107.5M; no additional borrowing capacity remains.
- Oaktree waived make-whole costs on the $30M draw if repaid before March 31, 2025.
- Second Amendment excludes the $30M draw from Total Leverage Ratio calculation.
- Milestone payment for Triescence was made on October 15, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224042600/0001493152-24-042600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224042600/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer